Biosimilar Development News

  1. Lannett Expands Strategic Relationship To Include Biosimilar Fast-Acting Insulin 2/9/2021

    Lannett Company, Inc. (NYSE: LCI) today announced that it has added a new co-development agreement for biosimilar insulin aspart with its strategic alliance partners within the HEC Group of companies (HEC).

  2. Enzene Biosciences Ltd. Obtains Marketing Authorization For Its First Biosimilar Molecule In India 2/4/2021

    Recently Enzene Biosciences Ltd. announced that it has obtained Marketing Authorisation (MA) from Drug Controller General of India (DCGI) for Teriparatide - bioactive part of human parathyroid hormone (PTH), an anabolic approach to the treatment of Osteoporosis, compared to the anti-resorptive therapies such as bisphosphates and SERMs.

  3. Smarter Use Of Generic, Biosimilar And Value Added Medicines Will Ensure Equitable Access To Cancer Care 2/4/2021

    Europe’s Beating Cancer plan is a welcome milestone to drive focused policy frameworks for cancer care in Europe. To achieve its mission, the cancer plan must support sustainable policies that improve access to generic, biosimilar and value added medicines.

  4. Biocon Biologics To Offer Its Oncology Biosimilars Through Cancer Access Partnership In Over 30 Countries 2/4/2021

    Biocon Biologics Ltd., a fully integrated ‘pure play’ biosimilars company and a subsidiary of Biocon Ltd., has signed an agreement with the Clinton Health Access Initiative (CHAI) to expand access to lifesaving cancer biosimilars in over 30 countries in Africa and Asia as a part of the Cancer Access Partnership (CAP).

  5. Global Bevacizumab Avastin Biosimilars Market Size Forecast Clinical Trials Development Report 2025 2/3/2021

    In the cancer therapeutics world as well as biotech space for the available biosimilars in the market for cancer patients, bevacizumab consists of large percentage in terms of market size and growth rate.

  6. Regarding The NDA Filing For YLB217, A Biosimilar Product Of Long-Acting Erythropoiesis Stimulating Agent Nesp 2/2/2021

    YL Biologics Ltd. (Head Office: Chuo-ku, Tokyo, President: Toshihiko Hibino) (YLB) announced that the NDA filing for YLB217, a biosimilar product of long-acting erythropoiesis stimulating agent Nesp, which YLB solely developed, was executed through Yoshindo Inc. (Head Office: Toyama, Japan, President: Hiroki Kitamura).

  7. Magellan Rx Medical Pharmacy Solution Impact: 90% Of New Authorizations For Oncology Biosimilars 2/1/2021

    Magellan Rx Management, a division ofMagellan Health, Inc., today released preliminary results from its oncology biosimilar medical pharmacy solution that targets new-to-market oncology therapeutic biosimilars.

  8. Global Gastric Cancer Forecast And Market Analysis Report 2020-2027 - Trastuzumab Biosimilars Are Now Available, Leading To A Sharp Decline In The Market Share Of Herceptin 1/29/2021

    The "Gastric Cancer Forecast and Market Analysis" drug pipelines has been added to ResearchAndMarkets.com's offering.

  9. Henlius Bevacizumab Has Received Clinical Trial Approval In Australia 1/29/2021

    Shanghai Henlius Biotech, Inc. announced that the filing of clinical trial for HLX04-O, a recombinant anti-VEGF humanized monoclonal antibody ophthalmic injection, for the treatment of wet age-related macular degeneration (wAMD) has been approved by the Therapeutic Goods Administration, Australia. 

  10. Bio-Thera Solutions Announces FDA Accepts Biologics License Application For BAT1706, A Proposed Biosimilar To Avastin 1/28/2021

    Bio-Thera Solutions, a commercial-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for BAT1706, a proposed biosimilar to Avastin (bevacizumab).